These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9086441)

  • 1. A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma.
    Engert A; Schnell R; Küpper F; Reiser M; Engelhard M; Wilhelm M; Lathan B; Baltes-Engler S; Winterhalter B; Scheulen ME; Dederichs B; Tesch H; Wörmann B; Diehl V
    Leuk Lymphoma; 1997 Feb; 24(5-6):513-22. PubMed ID: 9086441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.
    Reiser M; Schnell R; Straub G; Borchmann P; Wilhelm M; Ubelacker R; Wörmann B; Münch R; Diehl V; Engert A
    Leuk Lymphoma; 1998 Oct; 31(3-4):359-66. PubMed ID: 9869200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma.
    Garay G; Dupont J; Dragosky M; Nucifora E; Cacchione R; Schnidrig P; Fernández J; Abel-Alzueta ; Riveros D; Noviello V; Bèguelin R; Campestri R; Albera C; Nicastro M; Triguboff E
    Leuk Lymphoma; 1997 Aug; 26(5-6):595-602. PubMed ID: 9389366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.
    Abali H; Oyan B; Koc Y; Kars A; Barista I; Uner A; Turker A; Demirkazik F; Tekin F; Tekuzman G; Kansu E
    Am J Clin Oncol; 2005 Jun; 28(3):264-9. PubMed ID: 15923799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma.
    Salman H; Perez A; Sparano JA; Ratech H; Negassa A; Hopkins U; Villani G; Fuks J; Wiernik PH
    Am J Clin Oncol; 2003 Aug; 26(4):338-43. PubMed ID: 12902881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
    Coleman M; Leonard J; Shuster MW; Kaufman TP
    Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of ifosfamide in the treatment of relapsed and refractory lymphoma.
    Reiser M; Bredenfeld H; Engert A; Diehl V
    Eur J Haematol Suppl; 2001 Jul; 64():37-40. PubMed ID: 11486400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [DNCE regimen for treatment of refractory or relapsed aggressive and highly aggressive non-Hodgkin lymphoma].
    Liu XM; Wang HQ; Zhang HL; Qiu LH; Li W; Li LF; Cui XZ; Liu PF; Hao XS
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):779-82. PubMed ID: 19173813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European experience with ifosfamide in lymphomas.
    von Kalle AK; Schaadt M; Diehl V
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
    Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
    Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
    Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.
    Moskowitz CH; Bertino JR; Glassman JR; Hedrick EE; Hunte S; Coady-Lyons N; Agus DB; Goy A; Jurcic J; Noy A; O'Brien J; Portlock CS; Straus DS; Childs B; Frank R; Yahalom J; Filippa D; Louie D; Nimer SD; Zelenetz AD
    J Clin Oncol; 1999 Dec; 17(12):3776-85. PubMed ID: 10577849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of patients with high-grade non-Hodgkin's lymphoma aged over 70 years with an all-oral regimen combining idarubicin, etoposide and alkylators.
    Morra E; Gargantini L; Nosari A; Barbarano L; Pungolino E; Santoleri L; Bernuzzi P
    Crit Rev Oncol Hematol; 2000 Aug; 35(2):95-100. PubMed ID: 10936466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a combination of idarubicin, etoposide and intermediate-dose cytosine arabinoside as salvage therapy in relapsing or resistant unfavorable lymphoma.
    Brusamolino E; Passamonti F; Pagnucco G; Castagnola C; Lazzarino M; Bernasconi C
    Haematologica; 1998 Apr; 83(4):323-8. PubMed ID: 9592982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.